ArticleThe Journal of infectious diseases2008
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.
Article in The Journal of infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- Uncovering Resistance to Hepatitis C Virus Infection: Scientific Contributions and Unanswered Questions in the Irish Anti-D Cohort.Pathogens (Basel, Switzerland) · 2022Review
- Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.Viruses · 2021Review
- Circulating CXCR3Scientific reports · 2019Article
- SCARB1 variants and HCV infection: Host susceptibility is lost in translation.Journal of hepatology · 2017Article
- Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.Journal of viral hepatitis · 2016Article
- Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?Infectious agents and cancer · 2016Review
- Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort Study.Annals of internal medicine · 2015Observational
- Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.International journal of molecular sciences · 2015Article
- Trace amounts of sporadically reappearing HCV RNA can cause infection.The Journal of clinical investigation · 2014Article
- Immune responses to HCV and other hepatitis viruses.Immunity · 2014Review
- Protective immunity against hepatitis C: many shades of gray.Frontiers in immunology · 2014Review
- Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.Hepatitis monthly · 2014Article
- Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection.Nature medicine · 2013Article
- The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity.Gastroenterology · 2013Article
- Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study.The Journal of infectious diseases · 2013Article
- Two distinct functional patterns of hepatitis C Virus (HCV)-specific T cell responses in seronegative, aviremic patients.PloS one · 2013Article
- Hepatitis C virus-specific immune responses in noninjecting drug users.Journal of viral hepatitis · 2012Article
- New perspectives in occult hepatitis C virus infection.World journal of gastroenterology · 2012Article
- Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.Clinical and vaccine immunology : CVI · 2012Article
- Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.Journal of viral hepatitis · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundInjection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years).
methodsHCV-specific T cell responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gamma secretion, and cytotoxicity assays, whereas HCV-specific antibodies were assessed in enzyme immunoassays (EIAs), chemiluminescent assays, and in vitro neutralization assays.
resultsHCV-specific T cell proliferation and IFN-gamma production were more common in nonviremic EIA-positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003). They were also noted in 16 (62%) of 26 nonviremic EIA-negative IDUs. In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), compared with 9 (56%) of 16 nonviremic EIA-positive IDUs (P= .04) and 0 of 24 nonviremic EIA-negative IDUs. Nonviremic IDUs with nAbs were older (P= .0115) than those without nAbs, but these groups did not differ in terms of either injection drug use duration or HCV-specific T cell responses.
conclusionThe reduced risk of HCV persistence in IDUs previously recovered from HCV infection correlated with T cell responses, and prolonged antigenic stimulation appears to be required to maintain humoral responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.